Global /China /Healthcare /Drug Manufacturers - General /1681
chevron_leftBack
Consun Pharmaceutical Group Ltd. logo

Consun Pharmaceutical Group Ltd.

1681
SHEK: 1681 Delayed
16.22HKD 1.4%
2.07 USD
As of 14 June 2026, Consun Pharmaceutical Group Ltd. has a market cap of $1.74B USD, ranking #7711 globally and #1943 in China. It ranks #637 in the Healthcare sector, and #243 in the Drug Manufacturers - General industry.
Global Rank
7711
Country Rank
1943
Sector Rank
637
Industry Rank
243
Key Stats
Market Cap
$1.74BUSD
13.65B HKD
Enterprise Value
$1.26BUSD
9.88B HKD
Revenue (TTM)
$485.23MUSD
3.8B HKD
EBITDA (TTM)
$171.66MUSD
1.35B HKD
Net Income (TTM)
$153.07MUSD
1.2B HKD
EBITDA Margin
35%
Profit Margin
32%
PE Ratio
11.6
Forward PE
9.6
PS Ratio
3.6
PB Ratio
2.5
EV/EBITDA
7.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Meng An open_in_new
Employees
3,115
Founded
1997
Website
chinaconsun.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.4% 5.2% -5.3% -7.1% 6.7% 73%

News

Loading...

Markets

Exchange Ticker Price
Hong Kong Stock Exchange
MIC: XHKG
PRIMARY
1681
康臣药业集团有限公司
ISIN: KYG2524A1031
Shares Out.:
827.967M1 Shares Float: 451.228M2
TV:
SA:
YF:
GF:
BA:
MS:
16.22 HKD
Frankfurt Stock Exchange
MIC: XFRA
C1P
康臣药业集团有限公司
ISIN: KYG2524A1031
TV:
SA:
YF:
GF:
BA:
C1P
MS:
1.67 EUR
OTC Markets
MIC: OTCM
CPHGF
康臣药业集团有限公司
ISIN: KYG2524A1031
Shares Out.:
831.701M1 Shares Float: 407.237M2
TV:
SA:
YF:
GF:
BA:
MS:
1.12 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, an irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. The company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; and hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules. It also provides gastroenterology medicines, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People’s Republic of China.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.85B
364.89B CNY
3K%
44.9
603259
$49.64B
336.36B CNY
3K%
17.2
$28.52B
223.48B HKD
2K%
35.7
$18.8B
147.32B HKD
979%
162.3
$16.51B
111.89B CNY
848%
-
9926
$16.01B
125.46B HKD
819%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
44K%
38.1
JNJ
$547.28B
31K%
26.4
ABBV
$360.63B
21K%
97.4
$321.52B
256.25B CHF
18K%
19.9
AZN
$288.84B
215.59B GBP
16K%
27.6
NOVN
$274.65B
218.9B CHF
16K%
20.5
chevron_leftBack